Thu, Apr
22 New Articles

Aurobindo Pharma buys four biosimilar drugs from TL Biopharmaceutical

Industry Reports

Aurobindo Pharma Limited is pleased to announce the acquisition of four cell culture derived biosimilar products from TL Biopharmaceutical AG. As part of this agreement, TL will supply all the developmental data for four molecules and Aurobindo and/or its affiliates will develop, commercialize and market these products globally.

The branded market size of these four biosimilars, three of them monoclonal antibodies in oncology is very promising. Regulatory filing for these products is intended in the period 2020-22. 

Aurobindo is preparing to take its lead molecule from this transaction, a Bevacizumab biosimilar, for clinical trials in 2017. Bevacizumab is an anti-antiogenesis drug used in treating multiple-cancers including metastatic colon or rectal cancer, non-squamous and non-small cell lung cancers

This transaction is a strategic investment for future growth and will position Aurobindo as a strong player in the rapidly evolving biosimilars landscape. Building on these first four products licensed from TL, Aurobindo is expanding its diverse portfolio of eight more next wave of biosimilars ensuring a strong and diverse products pipeline. Aurobindo has set up a fully functional R&D center for biologics development and is also establishing a state-of-art manufacturing facility in Hyderabad, Telangana which would be ready by Q2, FY 18

Commenting on the strategic alliance, Mr. N. Govindarajan, Managing Director of Aurobindo Pharma Limited said: "We are impressed with TL's product developement as these are  developed to the highest standards of biosimilarity. This acquisition is in-line with our strategy of investing in complex products and is on important first step towards establishing Aurobindo's global biosimilar's portfolio.

About Aurobindo Pharma Limited:

Aurobindo Pharma Limited (www.aurobindo.com) , headquartered at Hyderabad, India, manufactures generic pharmaceuticals and active pharmaceutical ingredients. approved by several leading regulatory agencies like US FDA, UK MHRA, Japan PMDA, WHO, Health therapeutic/product areas encompassing Antibiotics, Anti-Retrovirals, CVS, CNS, Gastroenterologicals,Anti-Allergies and Anti-Diabetics, supported by an outstanding R&D set-up. The Company is marketing these products globally, in over 150 countries.

For further information, please contact:
Investor Relations
Phone: 040-66725401 / 66725000
Mobile: +91 98486 67906
Email: This email address is being protected from spambots. You need JavaScript enabled to view it.



Market Movers

Rogers Corporation

NYQ : ROG - 26 Apr, 4:02pm
+3.23 (+3.62%) After Hours:
Open 89.47 Mktcap 1.67B
High 92.79 52wk Hight 92.79
Low 89.39 52wk Low 51.98
Vol 339173 Avg Vol 120726
Eps 4.41 P/e 34.89
Currency: USD

Banco Santander, S.A. Sponsored

NYQ : SAN - 26 Apr, 4:04pm
-0.06 (-0.98%) After Hours:
Open 6.49 Mktcap 94.78B
High 6.54 52wk Hight 6.63
Low 6.47 52wk Low 3.60
Vol 5.23M Avg Vol 7.03M
Eps 0.49 P/e 15.05
Currency: USD

Merck & Company, Inc. (new)

NYQ : MRK - 26 Apr, 4:01pm
+0.40 (+0.64%) After Hours:
Open 62.63 Mktcap 172.15B
High 62.88 52wk Hight 66.80
Low 62.43 52wk Low 53.06
Vol 8.86M Avg Vol 9.02M
Eps 3.80 P/e 44.47
Currency: USD

Johnson & Johnson

NYQ : JNJ - 26 Apr, 4:00pm
+0.08 (+0.06%) After Hours:
Open 123.79 Mktcap 335.13B
High 124.26 52wk Hight 129.00
Low 123.48 52wk Low 109.32
Vol 5.02M Avg Vol 6.81M
Eps 7.10 P/e 20.76
Currency: USD

Pfizer, Inc.

NYQ : PFE - 26 Apr, 4:00pm
+0.09 (+0.27%) After Hours:
Open 33.86 Mktcap 201.47B
High 34.03 52wk Hight 37.39
Low 33.85 52wk Low 29.83
Vol 19.82M Avg Vol 23.31M
Eps 2.55 P/e 28.86
Currency: USD

Direxion Daily 10-Yr Treasury B

PCX : TYO - 26 Apr, 8:00pm
-0.08 (-0.55%) After Hours:
Open 14.51 Mktcap
High 14.56 52wk Hight 16.29
Low 14.41 52wk Low 12.60
Vol 26800 Avg Vol 10719
Eps P/e
Currency: USD
Sign up via our free email subscription service to receive notifications when new information is available.